Health and Healthcare

AbbVie : ABBV

All AbbVie Articles

612 Articles

Lee Jackson | Apr 20, 2015 at 9:10 AM EDT

3 Big Pharmaceutical Stocks Will Have Rising Q1 Earnings

In a new report, Cowen analysts have sights set on three major pharmaceutical stocks that they expect to have rising…

Lee Jackson | Mar 16, 2015 at 8:55 AM EDT

Should Investors Buy These 4 ‘Bad News’ Stocks for Big Gains?

24/7 Wall St. has found four good examples of blue-chip stocks that got a little tarnished recently for one reason…

Lee Jackson | Mar 6, 2015 at 8:20 AM EST

The Next 3 Likely Biotech Buyout Candidates

Here are three biotech stocks that a SunTrust analyst feels could be buyout candidates, in the wake of the Pharmacyclics…

Chris Lange | Mar 5, 2015 at 10:40 AM EST

Just How Expensive Is the Pharmacyclics Buyout?

News finally broke late Wednesday that there was an official buyout of Pharmacyclics in the works by AbbVie for $21…

Chris Lange | Feb 23, 2015 at 4:45 PM EST

Is Express Scripts 2015 Guidance Good Enough For All-Time Highs?

ThinkstockAfter the markets closed Monday, Express Scripts Holding Company (NASDAQ: ESRX) reported its fourth-quarter financial results as $1.39 in earnings…

Lee Jackson | Feb 23, 2015 at 9:05 AM EST

Jefferies 4 Top Pharmaceutical Stocks to Buy

One area that makes sense for growth investors is the large cap pharmaceuticals. Here are some the top pharmaceutical stocks…

Chris Lange | Feb 18, 2015 at 8:50 AM EST

Neurocrine Biosciences Announces New Offering

Neurocrine Biosciences has announced that it will have another public offering of its common stock to raise roughly $225 million.

Jon C. Ogg | Feb 9, 2015 at 8:45 AM EST

Top Analyst Upgrades and Downgrades: AbbVie, Alcoa, Apple, Deckers, Dish, Pfizer, Petrobras and More

Monday's top analyst upgrades, downgrades and initiations include AbbVie, Alcoa, Apple, Deckers Outdoor, Dish Network, Pfizer and Petrobras.

Lee Jackson | Feb 5, 2015 at 10:00 AM EST

Large Cap Pharmaceutical Stocks to Buy Despite Negative Pricing Headlines

If there is one thing that the pharmaceutical industry tries to shy away from it is the controversy over the…

Chris Lange | Feb 3, 2015 at 12:20 PM EST

What to Expect From Gilead Earnings

Tuesday after the U.S. markets close, Gilead Sciences will report its fourth-quarter financial results.

Chris Lange | Jan 30, 2015 at 8:55 AM EST

Are Humira Sales Enough to Lift AbbVie?

AbbVie reported better-than-expected fourth-quarter financial results Friday before the markets open.

Chris Lange | Jan 9, 2015 at 11:00 AM EST

Gilead Continues to Recover from Express Scripts Loss

Gilead Sciences was picked up by Anthem to provide its hepatitis C drug as the primary option for patients.

Chris Lange | Dec 29, 2014 at 10:45 AM EST

Is Gilead Already Coming Back Into Favor?

Is it possible that Gilead Sciences is already coming back into favor after just a week of being in the…

Chris Lange | Dec 23, 2014 at 12:15 PM EST

Analysts Predict Big Value Trap for Gilead Investors

Analysts are beginning to make their calls for what the future will hold for Gilead Sciences, AbbVie and Express Scripts.

Chris Lange | Dec 22, 2014 at 1:20 PM EST

What the AbbVie and Express Script Deal Means for Gilead

AbbVie and Express Scripts have entered into an exclusive agreement under which Express Scripts will distribute AbbVie's hepatitis treatment.

1 … 36 37 38 39 40 41

AbbVie : ABBV

All AbbVie Articles

3 Big Pharmaceutical Stocks Will Have Rising Q1 Earnings

Should Investors Buy These 4 ‘Bad News’ Stocks for Big Gains?

The Next 3 Likely Biotech Buyout Candidates

Just How Expensive Is the Pharmacyclics Buyout?

Is Express Scripts 2015 Guidance Good Enough For All-Time Highs?

Jefferies 4 Top Pharmaceutical Stocks to Buy

Neurocrine Biosciences Announces New Offering

Top Analyst Upgrades and Downgrades: AbbVie, Alcoa, Apple, Deckers, Dish, Pfizer, Petrobras and More

Large Cap Pharmaceutical Stocks to Buy Despite Negative Pricing Headlines

What to Expect From Gilead Earnings

Are Humira Sales Enough to Lift AbbVie?

Gilead Continues to Recover from Express Scripts Loss

Is Gilead Already Coming Back Into Favor?

Analysts Predict Big Value Trap for Gilead Investors

What the AbbVie and Express Script Deal Means for Gilead

He Retired at 58, Not 65. Here’s Why His Social Security Claiming Decision Matters More Than His Portfolio

What It Takes to Age in Place, And the Portfolio That Pays For It

He Retired at 55 With $1.2 Million in His 401(k). One Routine Paperwork Move Would Have Locked It All Up for Years

He Retired at 58, Not 65. Here's Why His Social Security Claiming Decision Matters More Than His Portfolio

What It Takes to Age in Place, And the Portfolio That Pays For It

He Retired at 58, Not 65. Here’s Why His Social Security Claiming Decision Matters More Than His Portfolio

What It Takes to Age in Place, And the Portfolio That Pays For It

AbbVie : ABBV

All AbbVie Articles

3 Big Pharmaceutical Stocks Will Have Rising Q1 Earnings

Should Investors Buy These 4 ‘Bad News’ Stocks for Big Gains?

The Next 3 Likely Biotech Buyout Candidates

Just How Expensive Is the Pharmacyclics Buyout?

Is Express Scripts 2015 Guidance Good Enough For All-Time Highs?

Jefferies 4 Top Pharmaceutical Stocks to Buy

Neurocrine Biosciences Announces New Offering

Top Analyst Upgrades and Downgrades: AbbVie, Alcoa, Apple, Deckers, Dish, Pfizer, Petrobras and More

Large Cap Pharmaceutical Stocks to Buy Despite Negative Pricing Headlines

What to Expect From Gilead Earnings

Are Humira Sales Enough to Lift AbbVie?

Gilead Continues to Recover from Express Scripts Loss

Is Gilead Already Coming Back Into Favor?

Analysts Predict Big Value Trap for Gilead Investors

What the AbbVie and Express Script Deal Means for Gilead

He Retired at 58, Not 65. Here’s Why His Social Security Claiming Decision Matters More Than His Portfolio

What It Takes to Age in Place, And the Portfolio That Pays For It

He Retired at 55 With $1.2 Million in His 401(k). One Routine Paperwork Move Would Have Locked It All Up for Years

Featured Reads

He Retired at 58, Not 65. Here's Why His Social Security Claiming Decision Matters More Than His Portfolio

What It Takes to Age in Place, And the Portfolio That Pays For It